Birmingham Women's NHS Foundation Trust said it is partnering with Illumina to develop an NIPT, which it hopes to start offering in September.
SeraCare is licensing UCSF's T21, T18, and T13 trophoblast cell line materials to develop NIPT reference materials.
Non-invasive prenatal screening tests are not only detecting fetal chromosomal abnormalities, but also some cases of maternal cancer.
The results are the most comprehensive picture so far of the patterns of abnormal NIPT results that could indicate a woman has a higher risk of carrying an unknown tumor.
The company's new clinical laboratory will provide interim and backup services for its customers.
The firm said in an SEC document that it plans to offer 6.25 million shares and expects net proceeds of up to $103.3 million.
The UK NIPT firm said that is creating a provision of £500,000 to cover expected expenses related to litigation involving Illumina.
The partners will leverage IME's rare cell isolation technology, a microchip containing a microfabricated filter membrane to isolate and enrich fetal cells from maternal blood.
Patent law experts said the ruling provides further clarity over what is and is not patentable within the broader molecular diagnostics field.
The results were presented at the ESHG meeting in Scotland this weekend and could potentially influence how NIPT is offered in those countries.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.